Holotranscobalamin as a Predictor of Vitamin B12 Status
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 378852256 | ||
| 003 | CHVBK | ||
| 005 | 20180305123326.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20031117xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2003.228 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.228 | ||
| 245 | 0 | 0 | |a Holotranscobalamin as a Predictor of Vitamin B12 Status |h [Elektronische Daten] |c [Anne-Mette Hvas, Ebba Nexo] |
| 520 | 3 | |a We report on the performance of a new test, holotranscobalamin, as compared to well established markers of vitamin B12 deficiency (plasma cobalamins, methylmalonic acid, and homocysteine). Holotranscobalamin was analyzed in 143 samples by a competitive radiobinding assay (Axis-Shield). Employing a cut-off value of 50 pmol/l, holotranscobalamin showed a sensitivity of 1.00 and a specificity of 0.89 as regards discriminating between individuals with test results indicating vitamin B12 deficiency (methylmalonic acid >0.70 μmol/l and plasma cobalamins <200 pmol/l, n = 35) and individuals with test results inside the reference intervals (methylmalonic acid <0.29 μmol/l and plasma cobalamins ≥200 pmol/l, n = 35). In a group (n = 37) with low plasma cobalamins (<200 pmol/l) and normal methylmalonic acid (<0.29 μmol/l), 27 individuals had low holotranscobalamin, and in nine of these individuals plasma homocysteine supported the deficiency state (homocysteine >15 μmol/l). Holotranscobalamin was low in 12 individuals with increased methylmalonic acid (>0.40 μmol/l) and normal plasma cobalamins ≥200 pmol/l) (n = 36), and plasma homocysteine supported the deficiency state in four of these individuals. We conclude that holotranscobalamin is likely to be a sensitive marker of vitamin B12 deficiency that also has a reasonable specificity. Large-scale clinical studies are warranted in order to clarify the usefulness of holotranscobalamin in the clinical setting. | |
| 540 | |a Copyright © 2003 by Walter de Gruyter GmbH & Co. KG | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 700 | 1 | |a Hvas |D Anne-Mette |4 aut | |
| 700 | 1 | |a Nexo |D Ebba |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/11(2003-11-17), 1489-1492 |x 1434-6621 |q 41:11<1489 |1 2003 |2 41 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2003.228 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2003.228 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hvas |D Anne-Mette |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nexo |D Ebba |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 41/11(2003-11-17), 1489-1492 |x 1434-6621 |q 41:11<1489 |1 2003 |2 41 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||